Pfizer Inc. (PFE) Tuesday said its phase 3 placebo controlled Oral Psoriatic Arthritis triaL or "OPAL Broaden" met its primary efficacy endpoints for the treatment of psoriatic arthritis. The company said the study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily in adult patients with active psoriatic arthritis. The study was done in patients with inadequate response to at least one conventional synthetic disease-modifying antirheumatic drug and who were tumor necrosis factor inhibitor na‹ve.
from RTT - Earnings http://ift.tt/1qneMmh
via IFTTT
No comments:
Post a Comment